Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non‐small‐cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two gene...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Pataer, Apar, Shao, Ruping, Correa, Arlene M., Behrens, Carmen, Roth, Jack A., Vaporciyan, Ara A., Wistuba, Ignacio I., Swisher, Stephen G.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010873/
https://ncbi.nlm.nih.gov/pubmed/29673125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1505
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados